Literature DB >> 21422415

Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.

Heidy C J Jaspers1, Berit M Verbist, Rafke Schoffelen, Vera Mattijssen, Piet J Slootweg, Winette T A van der Graaf, Carla M L van Herpen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21422415     DOI： 10.1200/JCO.2010.32.8351

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  51 in total

1.  Salivary duct carcinoma: A clinopathological report of 11 cases.

Authors:  Xiaofeng Huang; Jing Hao; Sheng Chen; Runzhi Deng
Journal:  Oncol Lett       Date:  2015-05-06       Impact factor: 2.967

2.  Sex disparities in salivary malignancies: Does female sex impact oncological outcome?

Authors:  Ximena Mimica; Marlena McGill; Ashley Hay; Daniella Karassawa Zanoni; Jatin P Shah; Richard J Wong; Alan L Ho; Marc A Cohen; Snehal G Patel; Ian Ganly
Journal:  Oral Oncol       Date:  2019-05-22       Impact factor: 5.337

3.  Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.

Authors:  Martin G Dalin; Alexis Desrichard; Nora Katabi; Vladimir Makarov; Logan A Walsh; Ken-Wing Lee; Qingguo Wang; Joshua Armenia; Lyndsay West; Snjezana Dogan; Lu Wang; Deepa Ramaswami; Alan L Ho; Ian Ganly; David B Solit; Michael F Berger; Nikolaus D Schultz; Jorge S Reis-Filho; Timothy A Chan; Luc G T Morris
Journal:  Clin Cancer Res       Date:  2016-04-21       Impact factor: 12.531

4.  Androgen deprivation therapy for metastatic salivary gland cancer.

Authors:  Arielle Elkrief; Ramy Saleh
Journal:  CMAJ       Date:  2018-08-20       Impact factor: 8.262

Review 5.  Genetic alterations in salivary gland cancers.

Authors:  Linda X Yin; Patrick K Ha
Journal:  Cancer       Date:  2016-02-29       Impact factor: 6.860

6.  Alterations associated with androgen receptor gene activation in salivary duct carcinoma of both sexes: potential therapeutic ramifications.

Authors:  Yoshitsugu Mitani; Pulivarthi H Rao; Sankar N Maity; Yu-Chen Lee; Renata Ferrarotto; Julian C Post; Lisa Licitra; Scott M Lippman; Merrill S Kies; Randal S Weber; Carlos Caulin; Sue-Hwa Lin; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

7.  Reciprocal and Autonomous Glucocorticoid and Androgen Receptor Activation in Salivary Duct Carcinoma.

Authors:  Yoshitsugu Mitani; Sue-Hwa Lin; Kristen B Pytynia; Renata Ferrarotto; Adel K El-Naggar
Journal:  Clin Cancer Res       Date:  2019-11-26       Impact factor: 12.531

8.  Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.

Authors:  Tatsuo Masubuchi; Yuichiro Tada; Shin-ichiro Maruya; Yoshiyuki Osamura; Shin-etsu Kamata; Kouki Miura; Chihiro Fushimi; Hideaki Takahashi; Daisuke Kawakita; Seiji Kishimoto; Toshitaka Nagao
Journal:  Int J Clin Oncol       Date:  2014-02-20       Impact factor: 3.402

9.  Trastuzumab for the treatment of salivary duct carcinoma.

Authors:  Sewanti A Limaye; Marshall R Posner; Jeffrey F Krane; Maria Fonfria; Jochen H Lorch; Deborah A Dillon; Aditya V Shreenivas; Roy B Tishler; Robert I Haddad
Journal:  Oncologist       Date:  2013-02-21

Review 10.  Clinicopathologic and immunohistochemical features of primary ductal adenocarcinoma of lacrimal gland: five new cases and review of literature.

Authors:  Toshinobu Kubota; Suzuko Moritani; Shu Ichihara
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-04-24       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.